<p>Groups were divided by quintiles of risk probability, in which the med-low / med / med-high / and highest risk groups had 2.17 (95% Confidence Interval [CI]: 1.70–2.78) / 4.83 (95% CI: 3.84–6.08) / 11.27 (95% CI: 8.99–14.14) / and 26.56 (95% CI: 21.07–33.48) -fold higher incidence of hepatocellular carcinoma compared to the lowest risk group, respectively.</p
*<p>Individuals with missing neurodegenerative disorders (ND) status were excluded in all models.</p...
<p>Discrimination ability at one-(a), three-(b), and five-(c) years after diagnosis with hepatocellu...
<p>The observed mortality is plotted logarithmically by group. A = Very Low, B = Moderately Low, C =...
<p>Cumulative incidence probability of primary liver cancer (A) and cumulative mortality probability...
<p>(a) Among patients with sustained virological response after 24 weeks (SVR24), the cumulative inc...
Observed mortality risk (A) at 56 days, (B) during inpatient stay, and (C) post-discharge in the der...
<p>(A) all anti-HCV seropositives (risk score <13 for low-risk, 13–18 for medium-risk, and ≥19 for h...
Background Among patients with cirrhosis, only those determined to be at risk for hepatocellular car...
Cumulative incidence rates for all-cause death/myocardial infarction in overall (A) and matched (B) ...
<p>Discrimination ability in the internal validation cohort at one-(a), three-(b), and five-(c) year...
Background: Information on the incidence and mortality of liver cancer can be useful for health prog...
<p>Cumulative risk of hepatocellular carcinoma after follow-up in (A) R.E.V.E.A.L.-HCV cohort and (B...
<p>Association of clinicopathological variables with high- or low-risk signature for cancer death an...
<p><b>Abbreviations:</b> CI, Confidence Interval; CHC, Community Health Center; GP, General Populati...
Primary liver cancer is one of the leading causes of death globally. Liver cancer has a unique geogr...
*<p>Individuals with missing neurodegenerative disorders (ND) status were excluded in all models.</p...
<p>Discrimination ability at one-(a), three-(b), and five-(c) years after diagnosis with hepatocellu...
<p>The observed mortality is plotted logarithmically by group. A = Very Low, B = Moderately Low, C =...
<p>Cumulative incidence probability of primary liver cancer (A) and cumulative mortality probability...
<p>(a) Among patients with sustained virological response after 24 weeks (SVR24), the cumulative inc...
Observed mortality risk (A) at 56 days, (B) during inpatient stay, and (C) post-discharge in the der...
<p>(A) all anti-HCV seropositives (risk score <13 for low-risk, 13–18 for medium-risk, and ≥19 for h...
Background Among patients with cirrhosis, only those determined to be at risk for hepatocellular car...
Cumulative incidence rates for all-cause death/myocardial infarction in overall (A) and matched (B) ...
<p>Discrimination ability in the internal validation cohort at one-(a), three-(b), and five-(c) year...
Background: Information on the incidence and mortality of liver cancer can be useful for health prog...
<p>Cumulative risk of hepatocellular carcinoma after follow-up in (A) R.E.V.E.A.L.-HCV cohort and (B...
<p>Association of clinicopathological variables with high- or low-risk signature for cancer death an...
<p><b>Abbreviations:</b> CI, Confidence Interval; CHC, Community Health Center; GP, General Populati...
Primary liver cancer is one of the leading causes of death globally. Liver cancer has a unique geogr...
*<p>Individuals with missing neurodegenerative disorders (ND) status were excluded in all models.</p...
<p>Discrimination ability at one-(a), three-(b), and five-(c) years after diagnosis with hepatocellu...
<p>The observed mortality is plotted logarithmically by group. A = Very Low, B = Moderately Low, C =...